BioVex Limited

BioVex Limited

Oncology drug development

Amgen announced the completion of the acquisition of BioVex Group, Inc. in 2011, for up to $1 billion. The transaction provides Amgen with BioVex’s lead product candidate, OncoVEXGM-CSF, a novel oncolytic vaccine in Phase 3 clinical development.